Wieduwilt, MJ, Metheny, L, Zhang, MJ, Wang, HL, Estrada-Merly, N, Marks, DI, Al-Homsi, AS, Muffly, L, Chao, N, Rizzieri, D, Gale, RP, Gadalla, SM, Cairo, M, Mussetti, A, Gore, S, Bhatt, VR, Patel, SS, Michelis, FV, Inamoto, Y, Badawy, SM, Copelan, E, Palmisiano, N, Kharfan-Dabaja, MA, Lazarus, HM, Ganguly, S, Bredeson, C, Perez, MAD, Cassaday, R, Savani, BN, Ballen, K, Martino, R, Wirk, B, Bacher, U, Aljurf, M, Bashey, A, Murthy, HS, Yared, JA, Aldoss, I, Farhadfar, N, Liu, HT, Abdel-Azim, H, Waller, EK, Solh, M, Seftel, MD, van der Poel, M, Grunwald, MR, Liesveld, JL, Kamble, RT, McGuirk, J, Munker, R, Cahn, JY, Lee, JW, Freytes, CO, Krem, MM, Winestone, LE, Gergis, U, Nathan, S, Olsson, RF, Verdonck, LF, Sharma, A, Ringden, O, Friend, BD, Cerny, J, Choe, H, Chhabra, S, Nishihori, T, Seo, S, George, B, Baxter-Lowe, LA, Hildebrandt, GC, de Lima, M, Litzow, M, Kebriaei, P, Hourigan, CS, Abid, MB, Weisdorf, DJ, Saber, W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances. 2022; 6(1)DOI:10.1182/bloodadvances.2021004916. PMID:34547770. IF:7.500(Q1/2D).

Mikulska, M, Knelange, N, Nicolini, LA, Tridello, G, Santarone, S, Di Bartolomeo, P, de la Camara, R, Cuellar, C, Velardi, A, Perruccio, K, Ljungman, P, Zaucha, J, Piekarska, A, Basak, G, Karakulska-Prystupiuk, E, Angelucci, E, Ciceri, F, Lupo-Stanghellini, MT, Fouillard, L, Garcia-Cadenas, I, Menconi, M, Blau, IW, Nassi, L, Cesaro, S, Styczynski, J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1)DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28.200(Q1/1D).

Serna, N, Falgas, A, Garcia-Leon, A, Unzueta, U, Nunez, Y, Sanchez-Chardi, A, Martinez-Torro, C, Mangues, R, Vazquez, E, Casanova, I, Villaverde, A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics. 2022; 14(1)DOI:10.3390/pharmaceutics14010192. PMID:35057088. IF:5.400(Q1/2D).

Wierda, WG, Allan, JN, Siddiqi, T, Kipps, TJ, Opat, S, Tedeschi, A, Badoux, XC, Kuss, BJ, Jackson, S, Moreno, C, Jacobs, R, Pagel, JM, Flinn, I, Pak, Y, Zhou, C, Szafer-Glusman, E, Ninomoto, J, Dean, JP, James, DF, Ghia, P, Tam, CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(34)DOI:10.1200/JCO.21.00807. PMID:34618601. IF:50.739(Q1/1D).

Dickinson, M, Briones, J, Herrera, AF, Gonzalez-Barca, E, Ghosh, N, Cordoba, R, Rutherford, SC, Bournazou, E, Labriola-Tompkins, E, Franjkovic, I, Chesne, E, Brouwer-Visser, J, Lechner, K, Brennan, B, Nuesch, E, DeMario, M, Ruttinger, D, Kornacker, M, Hutchings, M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 2021; 5(22)DOI:10.1182/bloodadvances.2021004619. PMID:34581757. IF:7.642(Q1/3D).

Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion. CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00518-6. PMID:36031661. IF:4.800(Q1/2D).

Del Principe, MI, Seidel, D, Criscuolo, M, Dargenio, M, Racil, Z, Piedimonte, M, Marchesi, F, Nadali, G, Koehler, P, Fracchiolla, N, Cattaneo, C, Klimko, N, Spolzino, A, Karapinar, DY, Demiraslan, H, Duarte, RF, Demeter, J, Stanzani, M, Melillo, LMA, Basilico, CM, Cesaro, S, Paterno, G, Califano, C, Delia, M, Buzzatti, E, Busca, A, Cornely, OA, Pagano, L, Alakel, N, Arsenijevi'c, VA, Camus, V, Falces-Romero, I, Itzhak, L, Kouba, M, Martino, R, Sedlacek, P, Weinbergerova, B. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope. MYCOSES. 2023; 66(1)DOI:10.1111/myc.13524. PMID:36064299. IF:4.100(Q1/2D).

Diaz-Santa, J, Rodriguez-Romanos, R, Coll, R, Osca, G, Pratcorona, M, Gonzalez-Bartulos, M, Garrido, A, Angona, A, Talarn, C, Tormo, M, Arnan, M, Vives, S, Salamero, O, Tuset, E, Lloveras, N, Diez, I, Zamora, L, Bargay, J, Sampol, A, Cruz, D, Vila, J, Sitges, M, Garcia, A, Vall-Llovera, F, Esteve, J, Sierra, J, Gallardo, D. 5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. EUROPEAN JOURNAL OF HAEMATOLOGY. 2022; 109(6)DOI:10.1111/ejh.13862. PMID:36063368. IF:3.100(Q3/6D).